Evidence for SERDs Tx

CE / CME

The Expanding Evidence Base for Oral SERDs and Other ER-Targeting Agents
Credits Available

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Physicians ABIM MOC: maximum of 0.75 Medical Knowledge MOC point

Released: May 30, 2024

Expiration: May 29, 2025

Pretest

Progress
1 2 3
Course Completed
Please answer the questions below.
1.

A 46-yr-old woman underwent lumpectomy in left breast with 3.2-cm tumor that was found to be ER 90%, PgR 30%, and HER2 1+. SLN was found to be negative. Oncotype score was 16. She completed 5 yr of adjuvant tamoxifen and then at 6 yr from diagnosis was found to have bone metastases. Biopsy showed ER 60%, PgR 30%, HER2 1+ breast cancer. She started on ribociclib plus OFS and letrozole, but 2 yr afterwards is experiencing disease progression.

NGS testing shows an ESR1 mutation. What treatment would you recommend now?